Media-OutReach Newswire AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth points for performance
Media-OutReach Newswire The global leader in rabies vaccines, the serum-free iterative rabies vaccine of AIM Vaccine has submitted a pre-application for marketing registration
Media-OutReach Newswire AIM Vaccine’s heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval